Case number 2019-2396
Galderma Laboratories v. Teva Pharmaceuticals USA > Documents
| Date Field | Doc. No. | Description (Pages) |
|---|---|---|
| Apr 23, 2021 | 0 | GALDERMA LABORATORIES v. TEVA PHARMACEUTICALS USA [OPINION] [nonprecedential] (0) |
| Mar 6, 2020 | 60 | Mandate issued to the United States District Court for the District of Delaware. Service as of this date by the Clerk of Court. [676914] [19-2396, 20-1213] [JAB] [Entered: 03/06/2020 11:25 AM] (1) |
| Jan 29, 2020 | 59 | JUDGMENT. REVERSED AND REMANDED AS TO CASE NO. 2019-2396; DISMISSED AS TO CASE NO. 2020-1213. Terminated on the merits after submission on the briefs. COSTS: No Costs. Mandate to issue in due course. For information regarding costs, petitions for rehearing, and petitions for writs of certiorari click here. [666764] [19-2396, 20-1213] [JAB] [Entered: 01/29/2020 09:34 AM] (2) |
| Jan 29, 2020 | 58 | OPINION filed for the court by Moore, Circuit Judge; O'Malley, Circuit Judge and Stoll, Circuit Judge. Nonprecedential Opinion. [666760] [19-2396, 20-1213] [JAB] [Entered: 01/29/2020 09:33 AM] (17) |
| Jan 29, 2020 | 57 | Submitted ON THE BRIEFS. Panel: Judge: Moore , Judge: O'Malley, Judge: Stoll. [666743] [JAB] [Entered: 01/29/2020 09:12 AM] (0) |
| Jan 16, 2020 | 56 | 6 paper copies of the Corrected Appendix [54] received from Appellants Galderma Laboratories, L.P., Galderma S.A. and Galderma Skin Health S.A.. [663898] [CJF] [Entered: 01/16/2020 03:15 PM] (0) |
| Jan 16, 2020 | 55 | 6 paper copies of the Reply Brief [48] received from Appellants Galderma Laboratories, L.P., Galderma S.A. and Galderma Skin Health S.A. [663848] [CJF] [Entered: 01/16/2020 02:16 PM] (0) |
| Jan 15, 2020 | 54 | MODIFIED ENTRY: CORRECTED APPENDIX FILED for Galderma Laboratories, L.P., Galderma S.A., and Galderma Skin Health S.A. Number of Pages: 549. Service: 01/15/2020 by email. Paper copies of the corrected appendix are due within three business days (see order No. [34] and FCR 25(c)(1)(K)). [663318]--[Edited 01/15/2020 by MJL - compliance review complete] [Jamil Alibhai] [Entered: 01/15/2020 12:26 PM] (549) |
| Jan 15, 2020 | 53 | Notice of Correction to Doc No. [50], [49] for Appellants Galderma Laboratories, L.P., Galderma S.A. and Galderma Skin Health S.A.. Service: 01/15/2020 by email. [663313] [19-2396] [Jamil Alibhai] [Entered: 01/15/2020 12:24 PM] (4) |
| Jan 13, 2020 | 52 | Certificate of Compliance with Fed. Cir. R. 11(d) (Trial Court) for Cross-Appellant Teva Pharmaceuticals USA, Inc.. Service: 01/13/2020 by email. [662752] [19-2396] [William Burgess] [Entered: 01/13/2020 11:21 PM] (1) |
| Jan 13, 2020 | 51 | Certificate of Compliance with Fed. Cir. R. 11(d) (Trial Court) for Appellants Galderma Laboratories, L.P., Galderma S.A. and Galderma Skin Health S.A.. Service: 01/13/2020 by email. [662750] [19-2396] [Jamil Alibhai] [Entered: 01/13/2020 10:49 PM] (4) |
| Jan 13, 2020 | 50 | MODIFIED ENTRY: CONFIDENTIAL APPENDIX FILED for Galderma Laboratories, L.P., Galderma S.A., Galderma Skin Health S.A. and Teva Pharmaceuticals USA, Inc. Number of Pages: 565. Service: 01/13/2020 by email. Paper copies due 01/21/2020. [662734]--[Edited 01/15/2020 by JAB - compliance review complete]. This appendix has been corrected. See Doc. No. [54]. [Jamil Alibhai] [Entered: 01/13/2020 06:53 PM] (0) |
| Jan 13, 2020 | 49 | MODIFIED ENTRY: APPENDIX FILED for Galderma Laboratories, L.P., Galderma S.A., Galderma Skin Health S.A. and Teva Pharmaceuticals USA, Inc. Number of Pages: 565. Service: 01/13/2020 by email. [662731] --[Edited 01/15/2020 by JAB - compliance review complete]. This appendix has been corrected. See Doc. No. [54]. [Jamil Alibhai] [Entered: 01/13/2020 06:48 PM] (565) |
| Jan 13, 2020 | 48 | MODIFIED ENTRY: REPLY BRIEF FILED for Appellants Galderma Laboratories, L.P., Galderma S.A. and Galderma Skin Health S.A. Number of Pages: 29. Service: 01/13/2020 by email. Unless ordered otherwise, any responsive deadline runs from the date of service of this brief. See Fed. Cir. R. 31. Paper copies due 01/21/2020 [662730] --[Edited 01/15/2020 by JAB - compliance review complete] [Jamil Alibhai] [Entered: 01/13/2020 06:46 PM] (40) |
| Jan 7, 2020 | 47 | 6 paper copies of the Opening Brief [33] received from Appellants Galderma Laboratories, L.P., Galderma S.A. and Galderma Skin Health S.A.. [661380] [CJF] [Entered: 01/08/2020 08:11 AM] (0) |
| Jan 7, 2020 | 46 | 6 paper copies of the Opening Response Brief [44] received from Cross-Appellant Teva Pharmaceuticals USA, Inc.. [661378] [CJF] [Entered: 01/08/2020 08:11 AM] (0) |
| Jan 3, 2020 | 45 | Outstanding paper copies of all briefs must be submitted within five business days from the date of issuance of this notice. See Fed. Cir. R. 25(c)(1). [660640] [JAB] [Entered: 01/03/2020 02:43 PM] (0) |
| Dec 30, 2019 | 44 | MODIFIED ENTRY: BRIEF FILED for Cross-Appellant Teva Pharmaceuticals USA, Inc. Number of Pages: 67. Service: 12/30/2019 by email. Unless ordered otherwise, any responsive deadline runs from the date of service of this brief. See Fed. Cir. R. 31. [659669] --[Edited 01/02/2020 by JAB - compliance review complete] [William Burgess] [Entered: 12/30/2019 09:20 PM] (80) |
| Dec 12, 2019 | 43 | ORDER filed granting motion [23]. The district court's injunction is stayed pending further order of this court. Galderma's reply brief and the joint appendix must be submitted electronically no later than January 13, 2019. Oral argument has been removed from the March 2020 calendar. Oral argument will be scheduled prior to March, but only if the panel deems it necessary. Service as of this date by the Clerk of Court. [656023] [LMS] [Entered: 12/12/2019 12:44 PM] (2) |
| Dec 9, 2019 | 42 | RESPONSE of Cross-Appellant Teva Pharmaceuticals USA, Inc. to the clerk order to file a response/reply [41] , clerk order [41]. Service: 12/09/2019 by email. [654831] [19-2396] [William Burgess] [Entered: 12/09/2019 09:03 AM] (2) |
| Dec 6, 2019 | 41 | ORDER directing Teva to inform this court by Monday, December 9, 2019 at 3:00 pm whether it intends to brief the injunction issue. (see order for details) Service as of this date by the Clerk of Court. [654546] [19-2396, 20-1213] [LMS] [Entered: 12/06/2019 10:57 AM] (2) |
| Dec 6, 2019 | 40 | Official caption revised to reflect Cross-Appeal. The official caption is reflected on the electronic docket under the listing of the parties and counsel. Service as of this date by the Clerk of Court. [654527] [TAM] [Entered: 12/06/2019 10:25 AM] (0) |
| Dec 6, 2019 | 39 | Note to file: The following cases are associated:19-2396 (Lead) with 20-1213 (Cross-Appeal). FURTHER ENTRIES WILL BE ADDED TO THE LEAD APPEAL ONLY. [654523] [19-2396, 20-1213] [TAM] [Entered: 12/06/2019 10:22 AM] (0) |
| Dec 2, 2019 | 38 | RESPONSE of Appellee Teva Pharmaceuticals USA, Inc. to the court order for expedited response or reply [35] , court order [35]. Service: 12/02/2019 by email. [653380] [19-2396] [Leora Ben-Ami] [Entered: 12/02/2019 09:08 PM] (18) |
| Dec 2, 2019 | 37 | RESPONSE of Appellants Galderma Laboratories, L.P., Galderma S.A. and Galderma Skin Health S.A. to the court order for expedited response or reply [35] , court order [35]. Service: 12/02/2019 by email. [653352] [19-2396] [Jamil Alibhai] [Entered: 12/02/2019 06:42 PM] (5) |
| Dec 2, 2019 | 36 | REMINDER: All counsel of record are reminded of their responsibility per Fed. Cir. R. 47.4(a) and Fed. Cir. R. 47.3 to promptly submit an amended Certificate of Interest (COI) and/or Entry of Appearance (EOA) as information changes during the pendency of the appeal. Failure to comply with these Rules may delay the timely processing of your case or result in adverse action. [CLERK'S NOTE: Attorney Chad Ray's contact information listed on the brief does not match the contact information on the account. Please update ECF account information at www.pacer.gov] [653109] [TAM] [Entered: 12/02/2019 11:30 AM] (0) |
| Nov 25, 2019 | 35 | ORDER filed directing the parties to respond, within seven days from the date of this order, whether the court lacks jurisdiction or whether it would be inappropriate under these circumstances for the court to consider Teva's motion. Service as of this date by the Clerk of Court. [652061] [LMS] [Entered: 11/25/2019 11:45 AM] (2) |
| Nov 25, 2019 | 34 | ORDER filed granting motion [22] to modify the caption. The revised official caption is reflected in the order. The motion to expedite [21] is granted to the extent that Teva's response brief is due no later than December 30, 2019; Galderma's reply brief and the joint appendix are due no later than January 13, 2020. Galderma is directed to file six paper copies of the reply brief and the joint appendix within three business days of the court's acceptance for filing of those documents. The appeal will be placed on the March 2020 oral argument calendar. No extensions of time should be anticipated. Service as of this date by the Clerk of Court. [652056] [LMS] [Entered: 11/25/2019 11:24 AM] (2) |
| Nov 21, 2019 | 33 | MODIFIED ENTRY: OPENING BRIEF FILED for Appellants Galderma Laboratories, L.P., Galderma S.A. and Galderma Skin Health S.A.. Number of Pages: 38. Service: 11/21/2019 by email. [651475] --[Edited 12/02/2019 by TAM - compliance review complete] [Jamil Alibhai] [Entered: 11/21/2019 04:53 PM] (152) |
| Nov 21, 2019 | 32 | Entry of appearance for Chad J. Ray as of counsel for Appellants Galderma Laboratories, L.P., Galderma S.A. and Nestle Skin Health S.A.. Service: 11/21/2019 by email. [651325] [19-2396] [Chad Ray] [Entered: 11/21/2019 02:13 PM] (2) |
| Nov 18, 2019 | 31 | REPLY of Appellee Teva Pharmaceuticals USA, Inc. to response [29]. Service: 11/18/2019 by email. [650344] [19-2396] [William Burgess] [Entered: 11/18/2019 05:54 PM] (19) |
| Nov 15, 2019 | 30 | Confidential PLAINTIFFS-APPELLANTS OPPOSITION TO EMERGENCY MOTION FOR STAY OF INJUNCTION PENDING APPEAL filed by Appellants Galderma Laboratories, L.P., Galderma S.A. and Nestle Skin Health S.A. corresponding to Doc. No. [29]. Service: 11/15/2019 by email. [649743] [19-2396] [Jamil Alibhai] [Entered: 11/15/2019 05:00 PM] (0) |
| Nov 15, 2019 | 29 | RESPONSE of Appellants Galderma Laboratories, L.P., Galderma S.A. and Nestle Skin Health S.A. to the motion [23] filed by Appellee Teva Pharmaceuticals USA, Inc., motion [23] filed by Appellee Teva Pharmaceuticals USA, Inc.. Service: 11/15/2019 by email. [649742] [19-2396] [Jamil Alibhai] [Entered: 11/15/2019 04:56 PM] (197) |
| Nov 13, 2019 | 28 | Entry of appearance for Chase A. Cobern as of counsel for Appellants Galderma Laboratories, L.P., Galderma S.A. and Nestle Skin Health S.A.. Service: 11/13/2019 by email. [649111] [19-2396] [Chase Cobern] [Entered: 11/13/2019 05:32 PM] (2) |
| Nov 13, 2019 | 27 | Entry of appearance for Kelly P. Chen as of counsel for Appellants Galderma Laboratories, L.P., Galderma S.A. and Nestle Skin Health S.A.. Service: 11/13/2019 by email. [649091] [19-2396] [Kelly Chen] [Entered: 11/13/2019 04:37 PM] (2) |
| Nov 12, 2019 | 26 | RESPONSE of Appellee Teva Pharmaceuticals USA, Inc. to the motion to expedite briefing [21] filed by Appellants Galderma Laboratories, L.P., Galderma S.A. and Nestle Skin Health S.A.. Service: 11/12/2019 by email. [648436] [19-2396] [William Burgess] [Entered: 11/12/2019 07:56 AM] (5) |
| Nov 8, 2019 | 25 | ORDER filed directing Galderma to respond to the motion [23] no later than seven days from the date of filing of this order. Any reply in support of the motion [23] is due no later than three days thereafter. (Per Curiam). Service as of this date by the Clerk of Court. [648159] [LMS] [Entered: 11/08/2019 01:16 PM] (2) |
| Nov 7, 2019 | 24 | Confidential Appellee's Emergency Motion to Stay or Dissolve the F.R.C.P. 62(d) "Injunction Pending Appeal" Granted to the Losing Party filed by Appellee Teva Pharmaceuticals USA, Inc. corresponding to Doc. No. [23], corresponding to Doc. No. [23]. Service: 11/07/2019 by email, US mail. [647962] [19-2396] [William Burgess] [Entered: 11/07/2019 09:49 PM] (0) |
| Nov 7, 2019 | 23 | MOTION of Appellee Teva Pharmaceuticals USA, Inc. to lift injunction, for an emergency stay pending appeal under Rule 8/18 [Consent: opposed]. Service: 11/07/2019 by email. [647961] [19-2396] [William Burgess] [Entered: 11/07/2019 09:35 PM] (505) |
| Nov 6, 2019 | 22 | MOTION of Appellants Galderma Laboratories, L.P., Galderma S.A. and Nestle Skin Health S.A. to modify the official caption [Consent: unopposed]. Service: 11/06/2019 by email. [647549] [19-2396] [Jamil Alibhai] [Entered: 11/06/2019 08:12 PM] (6) |
| Nov 6, 2019 | 21 | MOTION of Appellants Galderma Laboratories, L.P., Galderma S.A. and Nestle Skin Health S.A. to expedite briefing schedule [Consent: unopposed]. Service: 11/06/2019 by email. [647548] [19-2396] [Jamil Alibhai] [Entered: 11/06/2019 08:00 PM] (13) |
| Nov 6, 2019 | 20 | NOTICE OF NON-COMPLIANCE: The submission of Appellants Galderma Laboratories, L.P., Galderma S.A. and Nestle Skin Health S.A., Amended Certificate of Interest [18], is not in compliance with the rules of this court (see attached). Compliant document due on 11/14/2019. Service as of this date by the Clerk of Court. [647500] [TAM] [Entered: 11/06/2019 04:09 PM] (1) |
| Nov 5, 2019 | 19 | Entry of appearance for Michael C. Wilson as of counsel for Appellants Galderma Laboratories, L.P., Galderma S.A. and Nestle Skin Health S.A.. Service: 11/05/2019 by email. [647104] [19-2396] [Michael Wilson] [Entered: 11/05/2019 05:09 PM] (2) |
| Nov 5, 2019 | 18 | Amended Certificate of Interest for Appellants Galderma Laboratories, L.P., Galderma S.A. and Nestle Skin Health S.A.. Service: 11/05/2019 by email. [647082] [19-2396] This document is non-compliant. See Doc No.[20] [Jamil Alibhai] [Entered: 11/05/2019 04:45 PM] (3) |
| Nov 5, 2019 | 17 | Entry of appearance for Evan Diamond as of counsel for Appellants Galderma Laboratories, L.P., Galderma S.A. and Nestle Skin Health S.A.. Service: 11/05/2019 by email. [647038] [19-2396] [Evan Diamond] [Entered: 11/05/2019 03:57 PM] (2) |
| Nov 5, 2019 | 16 | Entry of appearance for Vanessa Yen as of counsel for Appellants Galderma Laboratories, L.P., Galderma S.A. and Nestle Skin Health S.A.. Service: 11/05/2019 by email. [647015] [19-2396] [Vanessa Yen] [Entered: 11/05/2019 03:39 PM] (2) |
| Nov 5, 2019 | 15 | Entry of appearance for Gerald J. Flattmann, Jr. as of counsel for Appellants Galderma Laboratories, L.P., Galderma S.A. and Nestle Skin Health S.A.. Service: 11/05/2019 by email. [647012] [19-2396] [Gerald Flattmann] [Entered: 11/05/2019 03:36 PM] (2) |
| Oct 8, 2019 | 14 | Amended Certificate of Interest for Appellants Galderma Laboratories, L.P., Galderma S.A. and Nestle Skin Health S.A.. Service: 10/08/2019 by email. [641014] [19-2396] [Jamil Alibhai] [Entered: 10/08/2019 01:01 PM] (3) |
| Oct 4, 2019 | 13 | **TEXT ONLY** ORDER granting motion to extend time to file Appellant's opening brief [12] filed by Appellants Galderma Laboratories, L.P., Galderma S.A. and Nestle Skin Health S.A.. The opening brief is due 12/12/2019. Service as of this date by the Clerk of Court. This order has been issued without an attached document and is official and binding. [640379] [TAM] [Entered: 10/04/2019 02:21 PM] (0) |
| Oct 4, 2019 | 12 | MOTION of Appellants Galderma Laboratories, L.P., Galderma S.A. and Nestle Skin Health S.A. to extend the time to 12/12/2019 to file the Appellants' Opening Brief. [Consent: unopposed]. Service: 10/04/2019 by email. [640308] [19-2396] [Jamil Alibhai] [Entered: 10/04/2019 12:41 PM] (11) |
| Sep 30, 2019 | 11 | Corrected Entry of appearance for Jamil N. Alibhai as principal counsel for Appellants Galderma Laboratories, L.P., Galderma S.A. and Nestle Skin Health S.A.. Service: 09/30/2019 by email. [639047] [19-2396] [Jamil Alibhai] [Entered: 09/30/2019 12:01 PM] (2) |
| Sep 30, 2019 | 10 | NOTICE OF NON-COMPLIANCE: The submission of Appellants Galderma Laboratories, L.P., Galderma S.A. and Nestle Skin Health S.A., Entry of Appearance for Jamil N. Alibhai [6], is not in compliance with the rules of this court (see attached). Compliant document due on 10/07/2019. Service as of this date by the Clerk of Court. [638996] [TAM] [Entered: 09/30/2019 09:54 AM] (1) |
| Sep 27, 2019 | 9 | Docketing Statement for the Appellants Galderma Laboratories, L.P., Galderma S.A. and Nestle Skin Health S.A.. Service: 09/27/2019 by email. [638881] [19-2396] [Jamil Alibhai] [Entered: 09/27/2019 04:13 PM] (3) |
| Sep 27, 2019 | 8 | Certificate of Interest for Galderma Laboratories, L.P., Galderma S.A., and Nestle Skin Health S.A. Service: 09/27/2019 by email. [638880] [19-2396]--[Edited 09/30/2019 by MJL to add party filers] [Jamil Alibhai] [Entered: 09/27/2019 04:12 PM] (3) |
| Sep 27, 2019 | 7 | Docketing Statement for the Appellee Teva Pharmaceuticals USA, Inc.. Service: 09/27/2019 by email. [638878] [19-2396] [Leora Ben-Ami] [Entered: 09/27/2019 04:10 PM] (3) |
| Sep 27, 2019 | 6 | Entry of appearance for Jamil N. Alibhai as principal counsel for Appellants Galderma Laboratories, L.P., Galderma S.A. and Nestle Skin Health S.A.. Service: 09/27/2019 by email. [638877] [19-2396] This document is non-compliant. See Doc No.[10] [Jamil Alibhai] [Entered: 09/27/2019 04:09 PM] (2) |
| Sep 27, 2019 | 5 | Certificate of Interest for Appellee Teva Pharmaceuticals USA, Inc.. Service: 09/27/2019 by email. [638875] [19-2396] [Leora Ben-Ami] [Entered: 09/27/2019 04:08 PM] (3) |
| Sep 27, 2019 | 4 | Entry of appearance for William H. Burgess as of counsel for Appellee Teva Pharmaceuticals USA, Inc.. Service: 09/27/2019 by email. [638872] [19-2396] [Leora Ben-Ami] [Entered: 09/27/2019 04:05 PM] (2) |
| Sep 27, 2019 | 3 | Entry of appearance for John C. O'Quinn, P.C. as principal counsel for Appellee Teva Pharmaceuticals USA, Inc.. Service: 09/27/2019 by email. [638868] [19-2396] [Leora Ben-Ami] [Entered: 09/27/2019 04:02 PM] (2) |
| Sep 27, 2019 | 2 | Entry of appearance for Leora Ben-Ami as of counsel for Appellee Teva Pharmaceuticals USA, Inc.. Service: 09/27/2019 by email. [638865] [19-2396] [Leora Ben-Ami] [Entered: 09/27/2019 03:58 PM] (2) |
| Sep 13, 2019 | 1 | Appeal docketed. Received: 09/06/2019. [635242]Entry of Appearance due 09/27/2019. Certificate of Interest is due on 09/27/2019. Docketing Statement due 09/27/2019. Appellant's brief is due 11/12/2019. [TAM] [Entered: 09/13/2019 09:32 AM] (30) |
